Complement inhibition for the treatment of COVID-19 triggered thrombotic microangiopathy with cardiac failure: a case report.
Didar UtebayHarald SeegerAntonia M S MüllerSascha DavidPublished in: European heart journal. Case reports (2021)
The aetiology of cardiogenic shock observed in this patient cannot simply be explained by his focal and chronic coronary findings. Although viral myocarditis was not formally excluded, both the clinical features of TMA and the rapid resolution of all clinical signs and symptoms after pharmacological complement inhibition suggest a SARS-CoV-2-driven microangiopathic origin of heart failure.
Keyphrases
- sars cov
- heart failure
- respiratory syndrome coronavirus
- left ventricular
- coronary artery
- coronary artery disease
- coronavirus disease
- case report
- sleep quality
- combination therapy
- loop mediated isothermal amplification
- smoking cessation
- sensitive detection
- replacement therapy
- ejection fraction
- aortic valve
- acute heart failure